DSP-107 is under clinical development by KAHR medical and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DSP-107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DSP-107 (KAHR-107) is under development for the treatment of solid tumors including colon carcinoma, leukemia and squamous, non-squamous non-small cell lung cancer, colorectal cancer, relapsed/refractory AML, MDS or chronic myelomonocytic leukemia (CMML), previously untreated AML or MDS, in patients with relapsed/refractory MDS, CMML, diffuse large B-cell lymphoma and T-cell lymphoproliferative diseases and multiple myeloma. It is administered by intravenous route. The drug candidate consists of dual signaling SIRPalpha-41BBL fusion protein. It acts by targeting CD47 and 41BBL. The drug candidate is developed based on dual signaling proteins (DSP) platform.
KAHR medical overview
KAHR medical (KAHR), a subsidiary of Hadasit Bio-Holdings Ltd, is a biotechnology company. It develops novel drug platform based on bi-functional, immunotherapeutic fusion proteins for cancer indications. The company’s oncology pipeline is based on Dual Signaling Proteins (DSP) technology that enables development of ultra-active immunotherapeutic biological drugs. Its pipeline products include DSP105, DSP106 and DSP107 targeting PD-L1 expressing tumor cells representing T-cell mediated tumor destruction. The company’s products are used in multiple animal disease models for the treatment of cancer and autoimmune diseases and also links portions of two immune and cancer-related membrane proteins to develop fusion protein. KAHR is headquartered in Jerusalem, Israel.
For a complete picture of DSP-107’s drug-specific PTSR and LoA scores, buy the report here.